Dehydrozaluzanin C- derivative protects septic mice by alleviating over-activated inflammatory response and promoting the phagocytosis of macrophages

• Published in: International immunopharmacology 2024-05, Vol.132, p.111889-111889, Article 111889
• Main Authors: Zou, Ying-xiang, Xiang, Tian-nan, Xu, Li-rong, Zhang, Huan, Ma, Yu-he, Zhang, Lu, Zhou, Chun-xian, Wu, Xiao, Huang, Qi-lin, Lei, Biao, Mu, Jing-wen, Qin, Xiang-yang, Jiang, Xin, Zheng, Yue-juan
• Format: Article
• Language: English
• Subjects: Animals; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Cytokines - metabolism; Dehydrozaluzanin C-derivative; Disease Models, Animal; Inflammatory response; Klebsiella Infections - drug therapy; Klebsiella Infections - immunology; Klebsiella pneumoniae - drug effects; Lipopolysaccharides; Macrophages; Macrophages - drug effects; Macrophages - immunology; Male; Mice; Mice, Inbred C57BL; Phagocytosis; Phagocytosis - drug effects; RAW 264.7 Cells; Sepsis; Sepsis - drug therapy; Sepsis - immunology; Signal Transduction - drug effects
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/j.intimp.2024.111889

•DHZD as a potential HDT agent for severe infection.•DHZD ameliorates tissue damage (lung, kidney, and liver) and excessive inflammatory response induced by LPS or CRKP infection in mice.•DHZD promotes macrophage phagocytosis in a clathrin- and actin-dependent manner.•DHZD decreases LPS-stimulated expression of IL-6, TNF-α and MCP-1 via PI3K/Akt/p70S6K signaling pathway in macrophages. Host-directed therapy (HDT) is a new adjuvant strategy that interfere with host cell factors that are required by a pathogen for replication or persistence. In this study, we assessed the effect of dehydrozaluzanin C-derivative (DHZD), a modified compound from dehydrozaluzanin C (DHZC), as a potential HDT agent for severe infection. LPS-induced septic mouse model and Carbapenem resistant Klebsiella pneumoniae (CRKP) infection mouse model was used for testing in vivo. RAW264.7 cells, mouse primary macrophages, and DCs were used for in vitro experiments. Dexamethasone (DXM) was used as a positive control agent. DHZD ameliorated tissue damage (lung, kidney, and liver) and excessive inflammatory response induced by LPS or CRKP infection in mice. Also, DHZD improved the hypothermic symptoms of acute peritonitis induced by CRKP, inhibited heat-killed CRKP (HK-CRKP)-induced inflammatory response in macrophages, and upregulated the proportions of phagocytic cell types in lungs. In vitro data suggested that DHZD decreases LPS-stimulated expression of IL-6, TNF-α and MCP-1 via PI3K/Akt/p70S6K signaling pathway in macrophages. Interestingly, the combined treatment group of DXM and DHZD had a higher survival rate and lower level of IL-6 than those of the DXM-treated group; the combination of DHZD and DXM played a synergistic role in decreasing IL-6 secretion in sera. Moreover, the phagocytic receptor CD36 was increased by DHZD in macrophages, which was accompanied by increased bacterial phagocytosis in a clathrin- and actin-dependent manner. This data suggests that DHZD may be a potential drug candidate for treating bacterial infections.